9 Jan 2023
European Journal of Cancer: Phase 1b/2 trial of fruquintinib plus sintilimab in treating advanced solid tumours: The dose-escalation and metastatic colorectal cancer cohort in the dose-expansion phases
THE LANCET :
FRESCO-2, a global Phase III study of fruquintinib in refractory metastatic colorectal cancer
Learn More
THE LANCET HAEMATOLOGY:
ESLIM-01 Phase III Study: Sovleplenib for primary immune thrombocytopenia patients in China
Learn More
THE LANCET Respiratory Medicine
Savolitinib Phase IIIb confirmatory study in treatment-naive METex14 NSCLC patients in China
Learn More
2024 Full Year Financial Results
Learn More
Latest News
24 May 2024HUTCHMED Highlights Presentations at the 2024 ASCO Annual MeetingRead more 17 May 2024HUTCHMED Highlights Sovleplenib Phase III ESLIM-01 Study and Hematological Malignancy Programs Data to be Presented at the upcoming EHA2024 CongressRead more 14 May 2024HUTCHMED Initiates Phase II/III Trial of the Combination of Surufatinib and Camrelizumab for Treatment-Naïve Pancreatic Ductal Adenocarcinoma in Collaboration with HengruiRead more
14 May 2024HUTCHMED Initiates the RAPHAEL Registrational Phase III Trial of HMPL-306 for Patients with IDH1- and/or IDH2-Mutated Relapsed/Refractory Acute Myeloid Leukemia in ChinaRead more 26 Apr 2024HUTCHMED Announces Positive CHMP Opinion for Fruquintinib in Previously Treated Metastatic Colorectal Cancer Received by TakedaRead more 5 Apr 2024HUTCHMED Highlights Data to be Presented at AACR Congress 2024Read more 2 Apr 2024HUTCHMED and Innovent Jointly Announce NDA Acceptance in China for Fruquintinib Combination with Sintilimab for the Treatment of Advanced Endometrial Cancer with Priority Review StatusRead more See all
2000
FOUNDED
HCM
NASDAQ &
LONDON AIM
LONDON AIM
13
HKEX
>20
NOVEL DRUG CANDIDATES
CREATED BY IN-HOUSE
DISCOVERY ENGINE
CREATED BY IN-HOUSE
DISCOVERY ENGINE
4
APPROVED & MARKETED
PRODUCTS IN CHINA
PRODUCTS IN CHINA
1
APPROVED & MARKETED
PRODUCT IN THE US, EU & JAPAN
PRODUCT IN THE US, EU & JAPAN
~40
CLINICAL TRIALS WORLDWIDE
INCLUDING 13+ REGISTRATION STUDIES
INCLUDING 13+ REGISTRATION STUDIES
>150,000
PATIENTS TREATED BY
OUR NOVEL MEDICINES
OUR NOVEL MEDICINES
OUR SCIENCE
Our core research and development philosophy is to take a holistic approach and treat cancer and immunological diseases through multiple modalities and mechanisms. We have taken a science-focused approach to develop highly selective, potent and well-tolerated cancer therapies that are deliberately engineered to improve drug exposure and reduce off-target toxicities.
FOLLOW HUTCHMED ON SOCIAL MEDIA
